Two oral drugs for non-Hodgkin lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests two new oral drugs (TQB3909 and TQB3702) together for people with non-Hodgkin lymphoma. It is a first-in-human study, so doctors are looking for the right dose and checking safety. It may be an option if you have not had a stem cell transplant and your lymphoma has not spread to the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a type of lymphoma called non-Hodgkin's B-cell lymphoma (or a related lymphoma).
- Your lymphoma can be seen on scans or measured (you have at least one measurable spot).
- Your major organs (like heart, liver, kidneys) are working well enough.
- You are willing to use birth control during the study and for 6 months after (if you or your partner could become pregnant).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB2101 for people with advanced blood cancers that haven't improved with standard treatments. The goal is to see if the drug is safe and effective.
This trial tests a new pill called TQB3909 that may offer another option for patients with CLL/SLL who have tried other treatments. It is considered for patients whose cancer has relapsed or not responded to prior therapies, or who could not tolerate them.
This trial tests a new tablet (TQB3702) combined with standard immune-and-chemo therapy for certain types of B-cell lymphoma that have come back or not responded to previous treatment. It aims to see if the combination is safe and effective.
This trial tests an experimental oral capsule called TQB3019 for people with advanced blood cancers that have come back or not improved with other treatments. The goal is to see if the drug is safe and to find the right dose.
This phase 1 trial tests an experimental drug called TQB2252 for people with advanced cancers that have not responded to standard treatments. The drug blocks a protein called LAG3 to help the immune system attack cancer cells.
This trial tests TQB3909 tablets in people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has returned or did not respond to prior treatment. The goal is to see if the drug is safe and can shrink the cancer or improve control of the disease.
Hear when a new Hematologic Malignancy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.